RVL Pharmaceuticals PLC

Company Profile

RVL Pharmaceuticals PLC had its IPO on 2018-10-18 under the ticker symbol RVLP.

The company operates in the Healthcare sector and Biotechnology industry. RVL Pharmaceuticals PLC has a staff strength of 125 employees.

Stock update

Shares of RVL Pharmaceuticals PLC opened at $0.11 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.1 - $0.12, and closed at $0.11.

This is a +14.7% increase from the previous day's closing price.

A total volume of 3,454,596 shares were traded at the close of the day’s session.

In the last one week, shares of RVL Pharmaceuticals PLC have increased by +4.27%.

RVL Pharmaceuticals PLC's Key Ratios

RVL Pharmaceuticals PLC has a market cap of $12.16 million, indicating a price to book ratio of 1.9383 and a price to sales ratio of 2.9208.

In the last 12-months RVL Pharmaceuticals PLC’s revenue was $36.92 million with a gross profit of $43.07 million and an EBITDA of $-39390000. The EBITDA ratio measures RVL Pharmaceuticals PLC's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, RVL Pharmaceuticals PLC’s operating margin was -107.73% while its return on assets stood at -23.65% with a return of equity of -182.44%.

In Q2, RVL Pharmaceuticals PLC’s quarterly earnings growth was a positive 0% while revenue growth was a negative 2.2%.

RVL Pharmaceuticals PLC’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-0.73 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into RVL Pharmaceuticals PLC’s profitability.

RVL Pharmaceuticals PLC stock is trading at a EV to sales ratio of 3.0339 and a EV to EBITDA ratio of -2.6968. Its price to sales ratio in the trailing 12-months stood at 2.9208.

RVL Pharmaceuticals PLC stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$85.40 million

Total Liabilities

$68.39 million

Operating Cash Flow

$-959000.00

Capital Expenditure

$1.05 million

Dividend Payout Ratio

0%

RVL Pharmaceuticals PLC ended 2024 with $85.40 million in total assets and $0 in total liabilities. Its intangible assets were valued at $85.40 million while shareholder equity stood at $16.33 million.

RVL Pharmaceuticals PLC ended 2024 with $25000.00 in deferred long-term liabilities, $68.39 million in other current liabilities, 994000.00 in common stock, $-604723000.00 in retained earnings and $55.85 million in goodwill. Its cash balance stood at $19.16 million and cash and short-term investments were $19.16 million. The company’s total short-term debt was $57,955,000 while long-term debt stood at $0.

RVL Pharmaceuticals PLC’s total current assets stands at $25.75 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $1.93 million compared to accounts payable of $2.53 million and inventory worth $1.36 million.

In 2024, RVL Pharmaceuticals PLC's operating cash flow was $-959000.00 while its capital expenditure stood at $1.05 million.

Comparatively, RVL Pharmaceuticals PLC paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$0.11

52-Week High

$2.99

52-Week Low

$0.09

Analyst Target Price

$3.2

RVL Pharmaceuticals PLC stock is currently trading at $0.11 per share. It touched a 52-week high of $2.99 and a 52-week low of $2.99. Analysts tracking the stock have a 12-month average target price of $3.2.

Its 50-day moving average was $0.34 and 200-day moving average was $0.9 The short ratio stood at 0.32 indicating a short percent outstanding of 0%.

Around 2700.8% of the company’s stock are held by insiders while 4909.9% are held by institutions.